Introduction {#acn3306-sec-0005}
============

Niemann--Pick type C (NPC) disease is a multiorgan storage disorder characterized by lysosomal accumulation of unesterified cholesterol (UC) and other lipids. Central nervous system (CNS) neurons widely display polymembranous cytoplasmic storage bodies with intracellular accumulation of GM2 and GM3 gangliosides in addition to UC. Patients exhibit progressive neurological decline. Mutations of the *NPC1* (\~ 95% of patients) or *NPC2* gene result in identical disease phenotype.[1](#acn3306-bib-0001){ref-type="ref"} The two encoded proteins, transmembrane NPC1 and soluble luminal NPC2, are thought to interact with UC and/or other lipids in a coordinated fashion to facilitate their egress from late endosomal/lysosomal (LE/LY) compartments.[2](#acn3306-bib-0002){ref-type="ref"}

Therapeutic strategies for NPC disease have included pharmacologic inhibition of substrate accumulation, increasing functionality of defective proteins, and targeting downstream sequelae such as inflammation and oxidative stress.[3](#acn3306-bib-0003){ref-type="ref"} The most efficacious therapy to date has been 2‐hydroxypropyl‐*β*‐cyclodextrin (HP*β*CD) which, following even subcutaneous administration to NPC1‐ or NPC2‐deficient mice, delays clinical onset, extends lifespan, and reduces UC and glycolipid accumulation within the CNS and other organs.[4](#acn3306-bib-0004){ref-type="ref"}, [5](#acn3306-bib-0005){ref-type="ref"}, [6](#acn3306-bib-0006){ref-type="ref"}, [7](#acn3306-bib-0007){ref-type="ref"}

Several mechanisms by which therapeutic correction is achieved have been proposed,[8](#acn3306-bib-0008){ref-type="ref"}, [9](#acn3306-bib-0009){ref-type="ref"} but the predominant view is that cyclodextrins (CDs) directly replace the function of NPC proteins within LE/LY compartments.[10](#acn3306-bib-0010){ref-type="ref"} Supporting this idea, HP*β*CD treatment is also found efficacious in mice deficient in both NPC proteins, but not in other diseases with functional NPC proteins and secondary lysosomal storage of cholesterol.[4](#acn3306-bib-0004){ref-type="ref"}, [10](#acn3306-bib-0010){ref-type="ref"} Exactly how CD acts to emulate NPC protein function or otherwise mediate CNS correction remains unclear.

CDs form host--guest complexes with a wide range of compounds and are commonly used as excipients. These enzyme‐modified starch derivatives are cyclic oligosaccharides toroid in shape with a hydrophobic inner cavity and hydrophilic exterior. There are three common "parent" types, *α*,*β*, and *γ*, composed of 6, 7, and 8 glucose units with increasing inner cavity diameter, respectively. Chemical derivatization of parent CDs is used to change solubility profiles, complexation properties, biodegradability, and toxicity.[11](#acn3306-bib-0011){ref-type="ref"}, [12](#acn3306-bib-0012){ref-type="ref"} Nearly, all therapy‐related studies on NPC animal models have used HP*β*CD, a *β*CD derivatized with hydroxypropyl side groups, yet have paid little attention to how different degrees of substitution (DS), that is, the number of hydroxypropyl groups per CD molecule, might affect efficacy.[6](#acn3306-bib-0006){ref-type="ref"}, [13](#acn3306-bib-0013){ref-type="ref"} Moreover, the potential efficaciousness of any other CD has been rarely investigated[10](#acn3306-bib-0010){ref-type="ref"}, [14](#acn3306-bib-0014){ref-type="ref"} and since studies show that HP*β*CD is ototoxic,[15](#acn3306-bib-0015){ref-type="ref"}, [16](#acn3306-bib-0016){ref-type="ref"}, [17](#acn3306-bib-0017){ref-type="ref"} identification of safer alternate CDs is greatly needed.

We administered nine different CDs to *Npc1* ^*−/−*^ and wild‐type (*Wt*) mice, and evaluated reduction of UC and gangliosides, and ototoxicity apparent through auditory brainstem responses (ABRs). To examine whether therapeutic efficacy related to ability of CD to interact with UC and possibly other accumulating lipids, we conducted parallel complexation assays with the same lots of CDs and UC, GM2 and GM3 gangliosides, and other lipids relevant to NPC disease: glucosylceramide, lactosylceramide, sphingosine, oleic acid, bis(monoacylglycero)phosphate (BMP), and 24(*S*)‐ and 27‐hydroxycholesterols (24(*S*)‐HC; 27‐HC). This is the first time a direct comparison of in vivo efficacy on disease correction and in vitro solubilization of lipids has been performed for a panel of CDs. Indeed, even just broad comparative complexation studies on many of the CDs and substrates examined here is limited. With the exception of oleic acid, posited to be a substrate of NPC1,[18](#acn3306-bib-0018){ref-type="ref"} all lipids we evaluated are elevated in NPC disease[1](#acn3306-bib-0001){ref-type="ref"}, [19](#acn3306-bib-0019){ref-type="ref"} and viable candidates for consequential interaction with CD. Sphingosine, glucosyl‐, and lactosyl‐ceramide are precursors for ganglioside synthesis, and sphingosine accumulation may be an initiating factor in the NPC disease cascade.[20](#acn3306-bib-0020){ref-type="ref"} BMP, enriched in internal LE membranes, can modulate cholesterol homeostasis and sphingolipid metabolism.[21](#acn3306-bib-0021){ref-type="ref"}, [22](#acn3306-bib-0022){ref-type="ref"} Finally, 24(*S*)‐ and 27‐HC traffic out of and into the brain,[23](#acn3306-bib-0023){ref-type="ref"}, [24](#acn3306-bib-0024){ref-type="ref"} and influence CNS cholesterol homeostasis,[25](#acn3306-bib-0025){ref-type="ref"} providing a potential means to impact neuronal storage from outside the CNS, in light of limited CNS entry of peripherally administered CD.

As CD could also promote membrane interactions, similar to what is observed for NPC2,[2](#acn3306-bib-0002){ref-type="ref"} and thereby facilitate efflux of lysosomal UC,[26](#acn3306-bib-0026){ref-type="ref"} we also evaluated each CD\'s ability to elicit membrane--membrane aggregation. We found distinct differences among CDs in both efficacy and ototoxicity, including identification of efficacious CDs with reduced ototoxicity, and evidence of substantial and differential complexation with several substrates that could contribute to the outcome of CD‐mediated therapy.

Materials and Methods {#acn3306-sec-0006}
=====================

Animals and treatments {#acn3306-sec-0007}
----------------------

BALB/cNctr‐*Npc1* ^*m1N*^ */*J heterozygote mice were bred to generate *Wt* and homozygous affected (*Npc1* ^*−/−*^) progeny and genotyped.[27](#acn3306-bib-0027){ref-type="ref"} From 7--21 days of age, mice were given subcutaneous injections every other day of 2.87 mmol/kg body weight of CD (from a 0.143 mol/L solution) or water alone (vehicle). This dosage corresponds to 4000 mg/kg for HP*β*CD (Sigma H107, St. Louis, MO), repeatedly shown to be efficacious.[4](#acn3306-bib-0004){ref-type="ref"}, [5](#acn3306-bib-0005){ref-type="ref"} Additional cyclodextrins included: three other HP*β*CD products differing in manufacturer and DS; 2‐hydroxypropyl‐*α*‐CD (HP*α*CD); 2‐hydroxypropyl‐*γ*‐CD (HP*γ*CD); sulfobutylether‐*β*‐CD (SBE*β*CD); sulfobutylether‐*α*‐CD (SBE*α*CD); and sulfobutylether‐*γ*‐CD (SBE*γ*CD) (Table [1](#acn3306-tbl-0001){ref-type="table-wrap"}). At 3 weeks of age, tissues were collected for analyses as described in Data S1.

###### 

Cyclodextrins used

  Cyclodextrin                                                                  Abbreviation   Source (cat\#)                                                                         Average molecular weight (Da)   Average degree of substitution (DS)
  ----------------------------------------------------------------------------- -------------- -------------------------------------------------------------------------------------- ------------------------------- -------------------------------------
  2‐Hydroxypropyl‐*α*‐CD                                                        HP*α*CD        Sigma Aldrich (39,0690--0)                                                             1180                            3.6
  Sulfobutylether‐*α*‐CD                                                        SBE*α*CD       Ligand Pharmaceuticals, Inc.[a](#acn3306-note-0002){ref-type="fn"} (CD‐084‐87)         1352                            2.4
  2‐Hydroxypropyl‐*β*‐CD (Sigma)                                                HP*β*CD        Sigma Aldrich (H107)                                                                   1396                            4.5
  2‐Hydroxypropyl‐*β*‐CD (Trappsol)                                             Trappsol       CTD, Inc. (THPB‐EC)                                                                    1541                            7.0
  2‐Hydroxypropyl‐*β*‐CD (Kleptose HP)                                          Kleptose HP    Roquette (346114)                                                                      1522                            6.7
  2‐Hydroxypropyl‐*β*‐CD (Kleptose HPB[b](#acn3306-note-0003){ref-type="fn"})   Kleptose HPB   Roquette (346111)                                                                      1387                            4.3
  Sulfobutylether‐*β*‐CD (*β* Captisol)                                         SBE*β*CD       Ligand Pharmaceuticals, Inc.[a](#acn3306-note-0002){ref-type="fn"} (CY‐04A‐05006.2F)   2163                            6.5
  Methyl‐*β*‐CD[c](#acn3306-note-0004){ref-type="fn"}                           M*β*CD         Sigma Aldrich (C4555)                                                                  1320                            13.2
  2‐Hydroxypropyl‐*γ*‐CD                                                        HP*γ*CD        Sigma Aldrich (H125)                                                                   1762                            8.0
  Sulfobutylether‐*γ*‐CD (*γ*Captisol)                                          SBE*γ*CD       Ligand Pharmaceuticals, Inc.[a](#acn3306-note-0002){ref-type="fn"} (P186‐188‐25)       1961                            4.2

Cyclodextrins originally obtained from CyDex Pharmaceuticals, Inc. (now Ligand Pharmaceuticals, Inc.).

Kleptose HPB is also known as VTS‐270.

M*β*CD used only in complexation assays; no in vivo work done due to toxicity.

John Wiley & Sons, Ltd

*Wt* mice used for ABR recordings were given weekly subcutaneous injections of 5.74 mmol/kg body weight of CD (from a 0.286 mol/L solution) or water alone starting at 8 weeks of age. All animal procedures were carried out according to guidelines approved by the Albert Einstein College of Medicine Institutional Animal Care and Use Committee.

Tissue staining for ganglioside and unesterified cholesterol {#acn3306-sec-0008}
------------------------------------------------------------

Vibratome sections were stained using immunohistochemistry (IHC) to detect GM2 and GM3 gangliosides, and using fluorescent filipin to detect UC essentially as described[28](#acn3306-bib-0028){ref-type="ref"} (Data S1). Widefield digital images were acquired on an Olympus AX70 microscope equipped with a CCD camera (MagnaFire, Optronics). Confocal images were acquired using a Zeiss 510 Meta DuoV2 laser scanning microscope with a 63 × (NA 1.4) objective.

Scoring changes in neuronal accumulation of unesterified cholesterol and gangliosides {#acn3306-sec-0009}
-------------------------------------------------------------------------------------

Three observers blinded to genotype and treatment independently scored representative coronal tissue sections of brain stained for UC, GM2, or GM3 ganglioside. Each coded slide was given a rating from 0 to 10 (0 = no accumulation, 10 = highest accumulation) for that substrate. Scoring was performed on the dorsomediolateral neocortex at \~ bregma − 2.00 mm. Each slide contained ≥ 3 coronal sections from one mouse (3--8 mice/treatment/stain, except filipin staining for Trappsol where *n* = 2 mice). Scoring was performed at 200×. Data were statistically analyzed with the multigroup nonparametric Kruskal--Wallis test and if appropriate, followed by Dunn\'s pairwise comparison post hoc test (*P* \< 0.05).

Biochemical analysis of gangliosides by TLC {#acn3306-sec-0010}
-------------------------------------------

Total lipids were extracted from cerebral hemispheres in choloroform--methanol--20% water[29](#acn3306-bib-0029){ref-type="ref"}, and gangliosides were further separated and quantified as in previous studies.[17](#acn3306-bib-0017){ref-type="ref"} Tissue from at least two animals per treatment was analyzed.

Auditory brainstem responses {#acn3306-sec-0011}
----------------------------

ABRs elicited by clicks monaurally presented at seven different sound pressure levels (SPLs) were used as an electrophysiological index of hearing thresholds in *Wt* mice administered different CDs and were assessed at 8, 12, and \~28 weeks of age.

Substrate solubilization by CDs {#acn3306-sec-0012}
-------------------------------

Biochemical determinations of substrate complexation by CDs were performed in at least one of three ways for each substrate. The first was a mobility shift technique where the target analyte\'s migration in a high‐performance liquid chromatography (HPLC) chromatogram with increasing amounts of CD was recorded, and the data used to calculate a binding constant.[30](#acn3306-bib-0030){ref-type="ref"} The second method also measured mobility shifts, but using capillary electrophoresis and derived an apparent binding constant based on that described.[31](#acn3306-bib-0031){ref-type="ref"}, [32](#acn3306-bib-0032){ref-type="ref"} Wherever possible, traditional phase solubility studies were conducted to obtain solubility isotherms and a binding constant essentially as described.[33](#acn3306-bib-0033){ref-type="ref"} The methodology employed for each substrate is indicated in Table [2](#acn3306-tbl-0002){ref-type="table-wrap"} and details of the techniques are given in Data S1.

###### 

Binding constants (M^‐1^) for CD interaction with Niemann‐Pick type C disease related compounds: unesterified cholesterol, brain‐relevant oxysterols, glucosylceramide, lactosylceramide, BMP, sphingosine, and oleic acid

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cyclodextrin                                         UC           GM2 ganglioside                                  GM3 ganglioside                          24(*S*)‐HC   27‐HC      Gluc‐cer                                 Lac‐cer                                  BMP   Sphingosine   Oleic Acid
  ---------------------------------------------------- ------------ ------------------------------------------------ ---------------------------------------- ------------ ---------- ---------------------------------------- ---------------------------------------- ----- ------------- ------------
  M*β*CD                                               7800 ± 110   2410 ± 250                                       1650 ± 170                               400 ± 41     980 ± 18   85                                       [a](#acn3306-note-0007){ref-type="fn"}   33    70            1520 ± 25

  HP*β*CD (Sigma)                                      4072 ± 22    [a](#acn3306-note-0007){ref-type="fn"}           [a](#acn3306-note-0007){ref-type="fn"}   117 ± 22     480 ± 14   [a](#acn3306-note-0007){ref-type="fn"}   [a](#acn3306-note-0007){ref-type="fn"}   18    3             215 ± 11

  Trappsol                                             3250 ± 80    ND                                               ND                                       110 ± 20     455 ± 11   [a](#acn3306-note-0007){ref-type="fn"}   ND                                       13    3             220 ± 21

  Kleptose HPB                                         4400 ± 66    [a](#acn3306-note-0007){ref-type="fn"}           [a](#acn3306-note-0007){ref-type="fn"}   98 ± 36      462 ± 8    [a](#acn3306-note-0007){ref-type="fn"}   ND                                       15    5             245 ± 18

  Kleptose HP                                          3050 ± 52    ND                                               ND                                       ND           ND         ND                                       ND                                       ND    ND            ND

  HP*γ*CD                                              31 ± 12      [a](#acn3306-note-0007){ref-type="fn"}           [a](#acn3306-note-0007){ref-type="fn"}   13           101 ± 3    5                                        [a](#acn3306-note-0007){ref-type="fn"}   7     5             22 ± 8

  SBE*γ*CD                                             25 ± 8       [a](#acn3306-note-0007){ref-type="fn"}; 14 ± 2   26 ± 3                                   25 ± 8       24         [a](#acn3306-note-0007){ref-type="fn"}   ND                                       5     14            13 ± 3

  SBE*β*CD                                             770 ± 29     10 ± 2;\                                         61 ± 9                                   70 ± 29      128 ± 11   5                                        [a](#acn3306-note-0007){ref-type="fn"}   3     18            62 ± 7
                                                                    45 ± 6                                                                                                                                                                                                                  

  HP*α*CD                                              105 ± 10     60 ± 18;\                                        36 ± 4                                   14 ± 3       11         10                                       [a](#acn3306-note-0007){ref-type="fn"}   8     8             44 ± 11
                                                                    52 ± 8                                                                                                                                                                                                                  

  SBE*α*CD                                             80 ± 13      75 ± 13;\                                        110 ± 17                                 7            9          5                                        ND                                       6     11            36 ± 9
                                                                    84 ± 9                                                                                                                                                                                                                  

  Method used [b](#acn3306-note-0008){ref-type="fn"}   1            3                                                3                                        1            1          2                                        2                                        2     2             1
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values reported are average ± SD.

UC, Unesterified cholesterol; Gluc‐cer, glucosylceramide; Lac‐cer, lactosylceramide; BMP, Bis (monoacyl‐glycero) phosphate; ND, Not done.

Below limit of detection.

Methods used for determination were: (1) solubility isotherm; (2) migration shift by high performance liquid chromatography; and (3) migration shift by capillary electrophoresis.

John Wiley & Sons, Ltd

Assay of membrane‐membrane interactions by different CDs {#acn3306-sec-0013}
--------------------------------------------------------

Large unilamellar vesicles (LUV) composed of 100 mol % egg phosphatidyl choline (EPC) were mixed with increasing concentrations of each CD, and absorbance at 350 nm (light scattering) was monitored (Versamax microplate reader; Molecular Devices, Sunnyvale, CA) over a 30 min period to assess membrane aggregation.[26](#acn3306-bib-0026){ref-type="ref"}

Results {#acn3306-sec-0014}
=======

Two‐week administration of different CDs to *Npc1* ^*−/−*^ mice results in varied cholesterol and ganglioside reduction in the brain {#acn3306-sec-0015}
------------------------------------------------------------------------------------------------------------------------------------

At 3 weeks, UC accumulation in the brain of untreated *Npc1* ^*−/−*^ mice (detectable as fluorescent filipin‐positive puncta in neurons, predominantly perikaryal) was differentially reduced by the nine CDs tested. HP*β*CD, HP*γ*CD, and SBE*γ*CD all showed comparable effective reduction of UC storage in the cerebral cortex (Fig. [1](#acn3306-fig-0001){ref-type="fig"}), and the four commercial HP*β*CDs showed indistinguishable results (Fig. S1). SBE*β*CD was less effective while *α*CD‐treated matched untreated *Npc1* ^*−/−*^ mice (Fig. [1](#acn3306-fig-0001){ref-type="fig"}). These observations were validated by blind scoring of stained tissue sections (Fig. [2](#acn3306-fig-0002){ref-type="fig"}A) which, versus untreated mice, showed statistically significant differences only for the HP*β*CDs and *γ*CDs. SBE*β*CD gave intermediate scores, which were not significantly different from either effective CDs or the ineffective *α*CDs.

![UC, and GM2 and GM3 ganglioside accumulation in the brain cells of 3‐week‐old mice treated with different CDs. Top row: Sample fluorescence photomicrographs of dorsal neocortex from untreated *Wt* mouse (A), and CD‐treated (B--G) and untreated (H) *Npc1* ^*−/−*^ mice, stained with filipin to detect UC. Virtually, all neurons in untreated *Npc1* ^*−/−*^ mice show positive cytoplasmic staining of UC (white spots) (H), whereas those in *Wt* mice are negative (A). Note that HP*β*CD (Sigma) (B), HP*γ*CD (C), and SBE*γ*CD (D) all show highly effective reduction in UC storage, while some UC remains with SBE*β*CD treatment (E). HP*α*CD (F) and SBE*α*CD (G) show UC storage grossly equivalent to untreated mice (H). Middle row: Sample brightfield photomicrographs of dorsal neocortex stained by immunoperoxidase to detect GM2 ganglioside. Dark brown puncta of GM2 immunoreactivity are evident throughout dorsal neocortical neurons in untreated *Npc1* ^*−/−*^ (H) in contrast to *Wt* (A) mice. The most effective reduction of GM2 in *Npc1* ^*−/−*^ mice is seen with HP*β*CD (B) and HP*γ*CD (C). Noticeably more remaining GM2 is evident in *Npc1* ^*−/−*^ mouse treated with SBE*γ*CD (D), and substantially more with SBE*β*CD and *α*CD treatments (E--G) which appear equivalent to untreated *Npc1* ^*−/−*^ mouse. Bottom row: Sample bright‐field photomicrographs of immunoperoxidase stained dorsal neocortex to detect GM3. Dark brown puncta of GM3 immunoreactivity are evident in neurons of untreated *Npc1* ^*−/−*^ mouse (H), though less abundant than GM2, and absent in *Wt* mouse cortex (A). The relative efficacy of different CDs to reduce GM3 ganglioside parallels UC reduction: HP*β*CD (B), HP*γ*CD (C), and SBE*γ*CD (D) are nearly indistinguishable from *Wt* (A); SBE*β*CD (E) shows an intermediate impact; and *α*CDs (F--G) show no appreciable reduction. *Wt* panels for GM2 and GM3 staining are split: Nissl counterstain in left half reveals cortical layers, marked by roman numerals. Scale bars = 50 *μ*m.](ACN3-3-366-g001){#acn3306-fig-0001}

![Results of scoring of neuronal UC and ganglioside accumulation in stained samples of dorsomediolateral neocortex from 3‐week‐old CD‐treated *Npc1* ^*−/−*^ mice. Tissue sections were scored blind by three independent observers on a scale of 0--10 (10 = greatest accumulation, 0 = no accumulation for that stain). Each point represents one observer\'s score of sections from one mouse, and horizontal lines show mean value. All stains were found to have evidence of significant differences between conditions (nonparametric ANOVA, *P* \< 0.0001). Color‐coded asterisks at top of each graph indicate level of significance found in post hoc pairwise statistical comparisons. (A) UC results based on filipin staining. All HP*β*CDs as well as HP*γ*CD and SBE*γ*CD treatment groups were significantly different from both vehicle and *α*CDs, and not significantly different (*P* ≥ 0.05) from one another. (Note that filipin data for Trappsol treatment was limited to two biological replicates.) SBE*β*CD produced a range of intermediate values that yielded no significant difference from any group, while *α*CDs showed no difference from vehicle. (B) GM2 ganglioside scores from immunohistochemical staining. Note that HP*β*CDs (Sigma, Kleptose HP, Kleptose HPB, and Trappsol) and HP*γ*CD were significantly different from vehicle and *α*CDs, and these effective CDs showed no difference between them. SBE*γ*CD produced intermediate scores and was not significantly different from any group with the exception of HP*γ*CD. SBE*β*CD scores were similar to vehicle and statistically different from all HP*β*CDs and HP*γ*CD. (C) GM3 ganglioside accumulation scores from immunohistochemical staining. The CDs with significantly different results from vehicle were all the HP*β*CDs, HP*γ*CD, and SBE*γ*CD, with no significant differences among these. SBE*β*CD produced intermediate values with no significant differences from any groups. Note that GM3 scoring results were remarkably equivalent to UC, with only some differences in confidence (*P*) level of statistical significance.](ACN3-3-366-g002){#acn3306-fig-0002}

In analogous evaluations of reduction of GM2 and GM3 ganglioside accumulation in cortical neurons, different CDs showed a relative efficacy which resembled, but not exactly matched, that for UC. For GM2 (Figs. [1](#acn3306-fig-0001){ref-type="fig"}, [2](#acn3306-fig-0002){ref-type="fig"}B), very effective statistically significant reduction was again observed with HP*β*CD and HP*γ*CD, but SBE*γ*CD was less effective and not statistically different from vehicle. SBE*β*CD and *α*CDs were indistinguishable from vehicle and significantly different from all HP*β*CD\'s and HP*γ*CD. The four different brands of HP*β*CDs tested (Figs S1, [2](#acn3306-fig-0002){ref-type="fig"}B) were all effective and not statistically different from one another. The relative effectiveness of CDs to reduce neocortical GM3 (Figs. [1](#acn3306-fig-0001){ref-type="fig"}, 2C and S1) essentially paralleled that seen for UC, again including no significant difference between the different HP*β*CDs.

Quantitative biochemical determinations of ganglioside content in cerebral homogenates (Fig. [3](#acn3306-fig-0003){ref-type="fig"}) showed trends that largely agreed with immunohistochemical data. For GM2, again all HP*β*CD brands and HP*γ*CD produced values close to that in *Wt* mice, while *α*CD values were not lower than untreated *Npc1* ^*−/−*^ mice. SBE*γ*CD also showed effectiveness but more so by thin layer chromatography (TLC) measures than by immunostaining and similarly, SBE*β*CD showed levels by TLC midway between *Wt* and untreated *Npc1* ^*−/−*^ while immunostaining scoring was close to untreated mice. For GM3, TLC data paralleled immunostaining patterns: all HP*β*CDs and *γ*CDs showed highly effective reduction; SBE*β*CD exhibited intermediate reduction; and *α*CDs were indistinguishable from untreated mice.

![Biochemical analysis of GM2 and GM3 ganglioside levels in the brain of mice treated with different CDs. Data are expressed as % of total gangliosides after thin layer chromatographic separation of extracts of cerebral homogenates from mice as indicated. While sample size of some groups was insufficient for statistical analysis, individual values are well clustered and confirm reduction of ganglioside levels in *Npc1* ^*−/−*^ mice treated with all the HP*β*CDs, HP*γ*CD, and SBE*γ*CD to levels approaching that in *Wt* mice. Ganglioside levels in *Npc1* ^*−/−*^ mice treated with SBE*β*CD showed an intermediate level of reduction, and HP*α*CD and SBE*α*CD‐treated *Npc1* ^*−/−*^ mice showed no reduction relative to untreated *Npc1* ^*−/−*^ mice. Each pip is a biological replicate and horizontal line shows the mean value.](ACN3-3-366-g003){#acn3306-fig-0003}

Considering UC and ganglioside data collectively, the overall order of efficacy was: all HP*β*CDs and HP*γ*CD ≥ SBE*γ*CD \> SBE*β*CD \> HP*α*CD and SBE*α*CD.

Two‐week administration of different CDs results in differential changes in cholesterol accumulation in liver {#acn3306-sec-0016}
-------------------------------------------------------------------------------------------------------------

Filipin staining of liver from untreated *Npc1* ^*−/−*^ mice revealed abundant accumulation of UC in hepatocytes and liver macrophages (Kupffer cells). HP*β*CD and HP*γ*CD showed the greatest clearance of hepatocytic UC storage, followed by SBE*γ*CD and then SBE*β*CD, while *α*CDs showed no improvement (Fig. [4](#acn3306-fig-0004){ref-type="fig"}). However, all CD treatments led to increased UC accumulation in macrophages in *Npc1* ^*−/−*^ mice, especially with SBE*β*CD, secondly HP*β*CD, and least with the *α*CDs. CD‐injected *Wt* mice also developed striking filipin‐positive macrophages with similar relative order of impact seen in *Npc1* ^*−/−*^ mice (Fig. [4](#acn3306-fig-0004){ref-type="fig"}).

![UC accumulation in liver of mice treated with different CDs. First two columns: (A) Filipin labeling of liver from untreated *Npc1* ^*−/−*^ mice revealed widespread accumulation of UC in hepatocytes and Kupffer cells while liver from untreated *Wt* mice exhibited only diffuse filipin labeling. (B--G) *Npc1* ^*−/−*^ mice treated with HP*β*CD, HP*γ*CD, and SBE*γ*CD showed UC reduction within hepatocytes (B, C, D), while SBE*β*CD, HP*α*CD, and SBE*α*CD treatments showed little to no difference from untreated *Npc1* ^*−/−*^ mice (E, F, G vs. A). Administration of all CDs to *Wt*, as well as disease mice, resulted in elevated UC accumulation in presumptive liver macrophages (Kupffer cells), but hepatocytes remained filipin‐negative in *Wt* mice. Note that the accumulation appeared less in *Wt* than in disease mice, but the order of impact by different CDs was similar for the two, for example, in both cases, SBE*β*CD showed the highest and HP*β*CD the second highest accumulation in Kupffer cells. Second two columns: Confocal images of liver sections double‐labeled with anti‐CD68 (magenta), to unambiguously delineate lysosomal membranes of Kupffer cells, and filipin (green). (A) CD68 + Kupffer cells exhibited conspicuous vesicular/vacuolar‐like filipin+ labeling in untreated *Npc1* ^*−/−*^ but not *Wt* mice. (B--G) CDs tested in *Npc1* ^*−/−*^ instigated varying degrees of increased UC accumulation in Kupffer cells. *Wt* mice administered different CDs also produced some UC accumulation specifically within Kupffer cells. Scale bars = 50 *μ*m (first two columns), 5 *μ*m (second two columns).](ACN3-3-366-g004){#acn3306-fig-0004}

Ototoxic effects of different CDs as measured by ABRs {#acn3306-sec-0017}
-----------------------------------------------------

ABRs were used as an electrophysiological index of hearing thresholds in *Wt* mice. Although vehicle‐treated mice had thresholds near 40 dB SPL consistent with normal hearing, mice treated with HP*β*CD had thresholds ≥100 dB SPL, indicative of extreme hearing loss (Fig. [5](#acn3306-fig-0005){ref-type="fig"}A, B). Nearly half the mice treated with HP*γ*CD had a threshold at 88 dB SPL, while all other groups (SBE*γ*CD, SBE*β*CD, HP*α*CD) had normal thresholds. Importantly, these trends persisted across the three time points spanning 20 weeks of treatment (Fig. S2). In all cases, mean hearing thresholds were statistically significantly higher for HP*β*CD‐treated mice than for any other group and no significant differences existed between vehicle‐treated and SBE*γ*CD, SBE*β*CD, or HP*α*CD‐treated mice (Fig. [5](#acn3306-fig-0005){ref-type="fig"}C). Thresholds for HP*γ*CD‐treated mice were intermediate between normal hearing and extreme hearing loss.

![Ototoxicity of different CDs as assessed by auditory brainstem responses (ABR) recordings at 12 weeks of age. (A) Representative ABR recordings from *Wt* mice administered different CDs are depicted. Several stereotypical ABR waveform components are evident, especially at the higher SPLs tested. Differences in waveform morphologies can be attributed to individual differences across mice and to slight variations in the placement of the subcutaneous needle electrodes. Waveforms obtained at threshold are plotted in red. HP*β*CD and HP*γ*CD traces show pronounced hearing loss while SBE*γ*CD, SBE*β*CD, and HP*α*CD traces demonstrate hearing thresholds equivalent to those of vehicle‐treated mice (\~ 40 dB). (B) Plot of hearing thresholds for individual mice reveals minute variability across mice treated with a particular CD with the exception of HP*γ*CD, in which hearing thresholds were more variable. (C) Two‐tailed t‐tests comparing mean thresholds for each pair of treatment groups revealed statistically significant differences in threshold only between HP*β*CD or HP*γ*CD and all other treatment groups.](ACN3-3-366-g005){#acn3306-fig-0005}

In vitro interaction of NPC‐relevant substrates with CDs {#acn3306-sec-0018}
--------------------------------------------------------

To determine whether efficacy of different CDs related to their capacity to interact with relevant substrates, in vitro assays were carried out utilizing the same lots of CDs used in vivo. Methyl‐*β*‐CD (M*β*CD), known for its high cholesterol solubilization, was included as a positive standard. In phase‐solubility isotherm studies with UC, M*β*CD showed the highest binding constant (K; equivalent to equilibrium constant) of 7800 ± 110 M^*−*1^, and all HP*β*CDs were closest to this with Ks between 3050 and 4400 M^*−*1^. K~SBE*β*CD~ was notably lower (770 ± 29 M^*−*1^), and the *γ*CDs and *α*CDs about another order of magnitude lower (Table [2](#acn3306-tbl-0002){ref-type="table-wrap"}). Complexation values (solubilization at a given concentration; Table [3](#acn3306-tbl-0003){ref-type="table-wrap"}) followed a similar pattern: M*β*CD \> HP*β*CDs (all with comparable values) \>\> SBE*β*CD \> SBE*γ*CD \> HP*γ*CD and *α*CDs. Thus, results with the *β*CDs and *α*CDs trended toward a positive correlation with degree of UC correction in brain, but *γ*CDs particularly HP*γ*CD, performed better in vivo than the complexation data might predict.

###### 

[a](#acn3306-note-0010){ref-type="fn"}Complexation values of CDs with Niemann‐Pick type C disease related compounds: unesterified cholesterol, brain‐relevant oxysterols, glucosylceramide, lactosylceramide, BMP, sphingosine, and oleic acid

  Cyclodextrin      UC/CD[c](#acn3306-note-0013){ref-type="fn"}   UC/CD[b](#acn3306-note-0012){ref-type="fn"}   24(*S*)‐HC/CD[b](#acn3306-note-0012){ref-type="fn"}   27‐HC/CD[b](#acn3306-note-0012){ref-type="fn"}   Gluc‐cer/CD[b](#acn3306-note-0012){ref-type="fn"}   Lac‐cer/CD[b](#acn3306-note-0012){ref-type="fn"}   BMP/CD[b](#acn3306-note-0012){ref-type="fn"}   Sphingosine/CD[c](#acn3306-note-0013){ref-type="fn"}   Oleic Acid/CD[b](#acn3306-note-0012){ref-type="fn"}
  ----------------- --------------------------------------------- --------------------------------------------- ----------------------------------------------------- ------------------------------------------------ --------------------------------------------------- -------------------------------------------------- ---------------------------------------------- ------------------------------------------------------ -----------------------------------------------------
  M*β*CD            0.2376                                        ND                                            0.0852                                                0.1770                                           [d](#acn3306-note-0014){ref-type="fn"}              0.0019                                             0.0067                                         1.3222                                                 0.1140
  HP*β*CD (Sigma)   0.0607                                        0.020                                         0.0229                                                0.0402                                           [d](#acn3306-note-0014){ref-type="fn"}              [d](#acn3306-note-0014){ref-type="fn"}             0.0229                                         0.3263                                                 0.0603
  Trappsol          0.0805                                        0.021, 0.023                                  0.0190                                                0.0360                                           ND                                                  ND                                                 ND                                             ND                                                     0.0660
  Kleptose HPB      0.0610                                        0.020                                         0.0177                                                0.0410                                           ND                                                  ND                                                 ND                                             ND                                                     0.0580
  Kleptose HP       0.0551                                        0.024                                         ND                                                    ND                                               ND                                                  ND                                                 ND                                             ND                                                     ND
  HP*γ*CD           0.0005                                        ND                                            0.0007                                                0.0621                                           [d](#acn3306-note-0014){ref-type="fn"}              [d](#acn3306-note-0014){ref-type="fn"}             0.0049                                         0.2059                                                 0.0886
  SBE*γ*CD          0.0017                                        ND                                            0.0009                                                0.0004                                           [d](#acn3306-note-0014){ref-type="fn"}              ND                                                 [d](#acn3306-note-0014){ref-type="fn"}         0.3929                                                 0.0167
  SBE*β*CD          0.0058                                        ND                                            0.0011                                                0.0063                                           [d](#acn3306-note-0014){ref-type="fn"}              [d](#acn3306-note-0014){ref-type="fn"}             [d](#acn3306-note-0014){ref-type="fn"}         1.5889                                                 0.0123
  HP*α*CD           0.0004                                        ND                                            0.0003                                                0.0352                                           [d](#acn3306-note-0014){ref-type="fn"}              [d](#acn3306-note-0014){ref-type="fn"}             0.0104                                         ND                                                     0.0384
  SBE*α*CD          0.0002                                        ND                                            0.0001                                                0.0031                                           ND                                                  ND                                                 ND                                             0.2709                                                 0.0260

UC, unesterified cholesterol; Gluc‐cer, glucosylceramide; Lac‐cer, lactosylceramide; BMP, Bis (monoacyl‐glycero) phosphate; ND, Not done.

Values reported are expressed as mol/mol and were determined from phase solubility isotherms.

Measurements taken with 250 mg CD/mL H~2~O.

Measurements taken with 50 mg CD/mL H~2~O.

Measurements taken with 10 mg CD/mL H~2~O.

Below limit of detection.

John Wiley & Sons, Ltd

Using the capillary electrophoresis mobility assay, CDs showed either no detectable interaction with ganglioside or Ks ≤ 110 M^*−*1^, except M*β*CD with a K \~ 2000 M^*−*1^. K values and their relative order in magnitude for different CDs were similar for both gangliosides, with *α*CDs \> *β* CDs \> *γ*CDs given equivalent side groups (Table [2](#acn3306-tbl-0002){ref-type="table-wrap"}). Furthermore, SBE‐CDs had higher Ks than equivalent parent HP‐CDs. The data suggested an inverse relationship between K and efficacy in ganglioside reduction, especially for GM2: the most efficacious, HP*β*CD and HP*γ*CD, showed undetectable interaction; ineffective *α*CDs had among the highest Ks, and SBE*γ*CD and SBE*β*CDs were intermediate in both regards. In further support, K values versus biochemical measurements of ganglioside reduction for the CDs, showed a statistically significant correlation and linear relationship (Fig. S3).

Solubility isotherm studies of the oxysterols showed K values about 10‐fold lower for 27‐HC than UC, and still lower for 24(*S*)‐HC (Table [2](#acn3306-tbl-0002){ref-type="table-wrap"}). However, the order of relative magnitude for both oxysterols considerably resembled that seen for with UC: M*β*CD \> HP*β*CDs (all brands similar) \> SBE*β*CD \> *γ*CDs \~ *α*CDs. Complexation values (Table [3](#acn3306-tbl-0003){ref-type="table-wrap"}) for 24(*S*)‐HC were highest for M*β*CD, then HP*β*CD (\~ 0.02 mol/mol), HP*γ*CD and SBE‐CDs (0.0007--0.0011 mol/mol), and *α*CDs (0.0001--0.0003 mol/mol), an order compatible with relative UC reduction in vivo, but differences between the latter two groups in complexation were small compared to UC reduction. Relative CD complexation with 27‐HC was quite different, with all HP‐CDs showing similar high values. Notably, HP*β*CD solubilization of 24(*S*)‐HC and 27‐HC was equal to and double that of UC, respectively (compare data columns 2--4, Table [3](#acn3306-tbl-0003){ref-type="table-wrap"}).

Evidence of stable interaction of the CDs used in vivo with the glycolipids, glucosylceramide, or lactosylceramide, was only detectable for glucosylceramide and limited to HP*γ*CD, SBE*β*CD, and *α*CDs, which showed low Ks (5--10 M^*−*1^) compared to 85 M^*−*1^ with M*β*CD in HPLC migration shift assays (Table [2](#acn3306-tbl-0002){ref-type="table-wrap"}). Sphingosine, showed an unusually high degree of complexation in phase solubility assays (Table [3](#acn3306-tbl-0003){ref-type="table-wrap"}) with M*β*CD and SBE*β*CD (\~ 1.6 mol/mol) and \~ 4‐ to 8‐fold less with other CDs. K values from shift assays (Table [2](#acn3306-tbl-0002){ref-type="table-wrap"}) ranged from 3 to 18 M^*−*1^, other than for M*β*CD (70 M^*−*1^). K values for BMP had a similar range, with HP*β*CDs the highest second to M*β*CD (Table [2](#acn3306-tbl-0002){ref-type="table-wrap"}). Phase solubility complexation values for BMP with the HP‐CDs were similar to or greater than with M*β*CD (Table [3](#acn3306-tbl-0003){ref-type="table-wrap"}). Lastly, complexation of oleic acid was greater than all other substrates (UC, oxysterols, ceramides, BMP) assayed with 50 mg/mL CD, except for 27‐HC:M*β*CD (Table [3](#acn3306-tbl-0003){ref-type="table-wrap"}). Following M*β*CD, the highest complexation and Ks (Table [2](#acn3306-tbl-0002){ref-type="table-wrap"}) were obtained with the HP*β*CDs and HP*γ*CD. HP‐CDs gave higher values than equivalent parent CDs with SBE substitutions.

Membrane interaction potential varies among CD derivatives {#acn3306-sec-0019}
----------------------------------------------------------

Using assays to quantify aggregation of phosphatidylcholine LUVs,[26](#acn3306-bib-0026){ref-type="ref"} we found M*β*CD and all HP*β*CD brands produced the greatest aggregation (Fig. [6](#acn3306-fig-0006){ref-type="fig"}), followed by HP*γ*CD ≈ SBE*α*CD \> SBE*γ*CD \> HP*α*CD ≈ SBE*β*CD. Only M*β*CD and HP*β*CDs values were statistically significantly different from control. Thus, the relative degree of membrane aggregation trended directly with reduction in neuronal UC and ganglioside accumulation obtained for the *β*‐ and *γ*‐CDs but not the *α*CDs.

![Membrane--membrane interaction of different CDs. Absolute change in absorbance after 30 min incubation period of 100 *μ*mol/L Large unilamellar vesicles (LUVs) with 1 mmol/L CD provides a measure of LUV aggregation (mean ± SE, *N* = 3 experiments). A highly significant statistical difference was found among samples (ANOVA, *P* \< 0.0001). Post hoc analysis (Tukey\'s multiple comparison test) showed that each of the HP*β*CDs and M*β*CD were significantly different from control (LUVs with buffer only) (*P* \< 0.01; asterisks), and there was no significant difference (*P* \> 0.05) among these CDs in pairwise comparisons. While the values for other CDs variably trended above background levels, this aggregation was not found statistically significantly different from control, nor between these other CDs. Similar results were obtained with CDs at 10 *μ*mol/L and 100 *μ*mol/L in three independent experiments (data not shown).](ACN3-3-366-g006){#acn3306-fig-0006}

Discussion {#acn3306-sec-0020}
==========

These studies yield several important findings. One, in evaluating the most extensive variety of CDs to date for UC and ganglioside reduction in the brain of *Npc1* ^*−/−*^ mice, we find HP*γ*CD as well as HP*β*CD, the primary CD studied for NPC therapy, are most effective. Furthermore, we show for the first time that SBE*γ*CD also provides significant improvement, along with lesser improvements by SBE*β*CD. Two, we find that HP*β*CD is one of the most efficacious CDs, with no significant difference among the four commercial HP*β*CDs, including Kleptose HPB, which supports its continued use in ongoing clinical trials (NCT01747135 and NCT02534844). Three, we further document HP*β*CD‐induced hearing loss[15](#acn3306-bib-0015){ref-type="ref"}, [16](#acn3306-bib-0016){ref-type="ref"}, [17](#acn3306-bib-0017){ref-type="ref"} and now demonstrate that repeated high‐dose administration of two efficacious CDs, SBE*γ*CD and SBE*β*CD, show no significant ototoxicity, raising important clinical implications for the future. Four, in parallel biochemical studies, we do not find a complete and positive correlation between CD effectiveness in apparent solubilization of cholesterol or ganglioside, or in phospholipid membrane interaction, and ability to reduce the accumulating substrates in the brain. These studies on NPC disease, which for the first time carried out side‐by‐side comparisons of CDs in vitro and in vivo, show efficacy cannot be fully predicted based on stable interaction in the aqueous phase with a single substrate.

Patient enrollment in a Phase 2/3 clinical trial began in September 2015 and continues use of the Kleptose HPB (aka VTS‐270) brand of HP*β*CD, yet there have been few comparative studies on CDs for their efficacy and none for ototoxicity. A recent study found partial rescue of Purkinje cells and modest increase in *Npc1* ^*−/−*^ mouse survival with HP*γ*CD, but parallel evaluation with HP*β*CD was lacking.[14](#acn3306-bib-0014){ref-type="ref"} It also found that HP*γ*CD was more effective than HP*β*CD in correcting molecular and functional abnormalities in induced neural progenitor cells from NPC patients, while we found these CDs indistinguishable in CNS efficacy in mice with treatment beginning at 1 week of age. Whether early intervention could improve long‐term outcome remains uncertain and could pose medical complications. The only other comparative report, in this case of 3 CDs, concluded that SBE*β*CD but not HP*α*CD matched HP*β*CD in normalizing cholesterol synthesis in liver and spleen 1 day after subcutaneous injection.[10](#acn3306-bib-0010){ref-type="ref"} While this measure implies correction of UC transport from the lysosome, our direct visualization of UC storage in cells after 2 weeks of treatment clearly showed HP*β*CD was more effective than SBE*β*CD in the liver and brain, cautioning that even longer term assessments are desirable given the protracted period of patient therapy. Beyond these previously considered CDs, we found SBE*γ*CD capable of liver and brain improvements though less efficacious than HP*β*CD and HP*γ*CD. Thus, HP‐substituted CDs had greater impact on storage reduction than did the equivalent SBE‐substituted parent rings. We found that the DS for HP*β*CD (4.5--7.0) made no significant difference in reduction of UC or ganglioside accumulation, in line with reports demonstrating no variance in extending *Npc1* ^*−/−*^ mouse survival[6](#acn3306-bib-0006){ref-type="ref"} or reducing total cholesterol in *Npc1* ^*−/−*^ cells.[13](#acn3306-bib-0013){ref-type="ref"}

All *β*‐ and *γ*‐CDs produced reduction of UC in hepatocytes, but interestingly led to an increase in vacuolar UC accumulation in Kupffer cells of *Npc1* ^*−/−*^ mice, as previously observed for HP*β*CD,[4](#acn3306-bib-0004){ref-type="ref"} and did so in *Wt* mice as well though to a lesser extent. Thus, given the latter had no deficiency, this suggests that CDs instigated accumulation in the Kupffer cells, not necessarily that a clearance mechanism in principle cannot operate in these cells. This accumulation might result from enhanced sequestration of extracellular CD as a consequence of the enhanced endocytic activity including phagocytosis associated with macrophages. Excessive levels of endocytosed CD in lysosomes, beyond what would typically result in other cell types such as neurons, could then entrap UC and counter its egress from the lysosome in *Wt*, as well as in *Npc1* ^*−/−*^ mice where egress is already compromised. This situation may be further aggravated by the fact that macrophages are known to significantly internalize exogenous sources of cholesterol through multiple pathways.[34](#acn3306-bib-0034){ref-type="ref"}, [35](#acn3306-bib-0035){ref-type="ref"} Alternatively, extracellular precomplexed CD:UC might be accumulated by macrophages, though it has been argued that such complexes are absent from circulation after subcutaneous HP*β*CD injections.[36](#acn3306-bib-0036){ref-type="ref"} In any case, our findings that HP*β*CD and SBE*β*CD showed the largest increase in UC within Kupffer cells and the greatest complexation with UC support the idea that macrophage accumulation of UC is linked to endocytosed CD. Future studies to quantify CD uptake by macrophages and investigate functional consequences would be worthwhile.

Reports of HP*β*CD‐induced ototoxicity with impact on hearing threshold in NPC1 cats and *Wt* mice[15](#acn3306-bib-0015){ref-type="ref"}, [16](#acn3306-bib-0016){ref-type="ref"}, [17](#acn3306-bib-0017){ref-type="ref"} have been a major concern in moving CD forward as a therapeutic agent. Importantly, we found that HP*γ*CD which was also therapeutically efficacious, showed significantly less ototoxicity than HP*β*CD in *Wt* mice, and that the equivalent SBE‐substituted *β*CD and *γ*CD, showed no ototoxicity as assessed by ABR measures. While these findings must be confirmed in *Npc1* ^*−/−*^ mice, a comparative study on HP*β*CD‐induced toxicity by several criteria on *Wt* and disease mice, indicated *Npc1* ^*−/−*^ mice were more resistant, not less, to toxic effects,[37](#acn3306-bib-0037){ref-type="ref"} suggesting these alternate CDs should not produce greater ototoxicity in *Npc1* ^*−/−*^ mice. It is unclear why HP*β*CD causes death of outer hair cells of the cochlea, which underlies the hearing loss,[16](#acn3306-bib-0016){ref-type="ref"} but our observed ototoxicity order of HP*β*CD \> HP*γ*CD \> HP*α*CD matches that reported for hemolysis and toxicity for other cell types.[38](#acn3306-bib-0038){ref-type="ref"}, [39](#acn3306-bib-0039){ref-type="ref"}, [40](#acn3306-bib-0040){ref-type="ref"} In addition, SBE*β*CD with \~ 7DS, such as we used, showed no hemolysis in contrast to HP*β*CD at equivalent concentrations.[41](#acn3306-bib-0041){ref-type="ref"} Correlations between hemolytic activity and degree of cholesterol solubilization have been reported (e.g.,[41](#acn3306-bib-0041){ref-type="ref"}, [42](#acn3306-bib-0042){ref-type="ref"}), but neither our UC:CD complexation data, nor data from any other substrate examined, showed clear predictive power for ototoxicity aside from the observation that HP*β*CD exhibited both the greatest ototoxicity and UC complexation. Multiple interactions of CD with different hair cell constituents, negative effects at the blood‐labyrinth barrier or even disruption of fragile perilymph homeostasis[43](#acn3306-bib-0043){ref-type="ref"} may contribute to toxicity.

Collectively, our therapeutic efficacy and toxicity data suggest that the two effects are to some extent separable and provide a basis for further investigation in *Npc1* ^*−/−*^ mice. Of particular interest is HP*γ*CD which showed equivalent efficacy to HP*β*CD but reduced ototoxicity and macrophage involvement, and SBE*γ*CD which elicited even fewer side effects but with some reduction in efficacy.

Given the known affinity of *β*CDs for cholesterol, the therapeutic action of HP*β*CD has been thought to arise from interaction with UC, be it in extracellular/interstitial fluid, at the plasma membrane or within LE/LYs. Indeed, the findings that both UC solubilization and storage reduction was far higher for the *β*CDs than the *α*CDs, and that HP*β*CD was better than SBE*β*CD in both regards, support this view. On the other hand, *γ*CDs appeared closer to HP*β*CD in efficacy but to *α*CDs in solubilization. Studies pertaining to CNS entry of CDs are inadequate to assert that differential access to neurons could account for these discrepancies and do not suggest *γ*CDs are more effective than *α*CDs in this regard.[44](#acn3306-bib-0044){ref-type="ref"}, [45](#acn3306-bib-0045){ref-type="ref"} Relative reduction of UC storage in the brain by different CDs was also very similar to that seen in hepatocytes, further suggesting that blood--brain barrier (BBB) penetrability was not a discriminatory factor. Should the critical mode of CD\'s action occur within LE/LYs, as many contend,[10](#acn3306-bib-0010){ref-type="ref"}, [46](#acn3306-bib-0046){ref-type="ref"}, [47](#acn3306-bib-0047){ref-type="ref"} it could promote UC egress through direct interactions with membranes.[26](#acn3306-bib-0026){ref-type="ref"} This may occur via diffusion of substrate directly from the membrane into the hydrophobic core of CD[48](#acn3306-bib-0048){ref-type="ref"}, [49](#acn3306-bib-0049){ref-type="ref"}, [50](#acn3306-bib-0050){ref-type="ref"} or CD may lower the activation energy for desorption from membrane into aqueous phase[10](#acn3306-bib-0010){ref-type="ref"}, [51](#acn3306-bib-0051){ref-type="ref"} followed by rapid transfer to an adjacent membrane, that is, movement of accumulated UC from LE/LY multilamellar membranes to the limiting membrane. In fact, we observed a trend for the different *β*‐ and *γ*CDs that showed the same order of potency for promoting membrane--membrane interaction (Fig. [6](#acn3306-fig-0006){ref-type="fig"}) as observed for reduction of UC storage. Thus, pure aqueous solubilization measurements may not be adequately predictive, but the exceedingly low values found for the *γ*CDs, especially HP*γ*CD, calls for consideration of yet other critical mechanisms. Studies directly comparing CDs for UC transfer between adjacent bilayer membranes could be insightful.

It is not clear why GM2 and GM3 accumulate in NPC disease or why HP*β*CD can counter this. Although speculated,[52](#acn3306-bib-0052){ref-type="ref"} there is no definitive evidence that the NPC proteins directly interact with gangliosides or their metabolic proteins. However, there is evidence of colocalization of gangliosides with UC in LE/LY, particularly striking for GM3, suggesting possible interdependence or association of ganglioside and UC accumulation.[20](#acn3306-bib-0020){ref-type="ref"}, [53](#acn3306-bib-0053){ref-type="ref"}, [54](#acn3306-bib-0054){ref-type="ref"}, [55](#acn3306-bib-0055){ref-type="ref"} We also found relative reduction of GM2, and even more so of GM3, to parallel efficacy of CDs for UC reduction, further arguing a close link between these compounds. These observations are also compatible with the prevailing view that CD mediates correction from within LE/LYs. Additionally, the CDs showed a significant inverse correlation between their Ks for GM2 or GM3 and their reduction of these gangliosides in brain (Fig. S3), suggesting detrimental effects of CD on ganglioside clearance. In fact, we observed a small increase in % GM2 and GM3 gangliosides in *Npc1* ^*−/−*^ mice treated with *α*CDs (which showed the highest Ks). It is conceivable that direct interaction with CDs modulated efficiency of ganglioside catabolism.[56](#acn3306-bib-0056){ref-type="ref"} On the other hand, reduction of ganglioside accumulation in LE/LY may arise indirectly. A recent in vitro study showed that elevated membrane cholesterol can inhibit GM2 activator protein function and efficiency of GM2 hydrolysis.[57](#acn3306-bib-0057){ref-type="ref"} Accordingly, CDs more effective at reducing stored UC should also produce greater GM2 reduction, which is what we found.

From the remaining substrates tested, of note were the traditional phase solubility measurements (Table [3](#acn3306-tbl-0003){ref-type="table-wrap"}) for sphingosine which included values even greater than 1 mol/mol with M*β*CD and SBE*β*CD suggesting formation of sphingosine:CD complexes of \> 1:1 stoichiometry. The potential therapeutic effects of CD through interaction with sphingosine merit further investigation, as sphingosine is elevated early in NPC disease and has been hypothesized to be an initiating pathogenetic factor for both UC and ganglioside storage.[20](#acn3306-bib-0020){ref-type="ref"}

Of all the substrates evaluated, the relative degree of complexation among CDs with 24(*S*)‐HC arguably best approached a correlation with UC storage reduction though this interaction too was imperfect and cannot explain the efficacy findings alone. The range of solubilization values of oxysterols, 0.0001--0.06 mol:mol CD, which resembled and approached levels seen with UC, is worth noting given the levels of HP*β*CD and the much lower concentration of oxysterols than cholesterol found in the circulation. After a single subcutaneous injection equal to the one we used, plasma HP*β*CD peaks at \~ 1.4 or 3.5 mmol/L, depending on mouse age.[7](#acn3306-bib-0007){ref-type="ref"} In *Wt* mice, 24(*S*)‐HC and 27‐HC are each found at \~ 0.1 *μ*mol/L, respectively, in plasma.[58](#acn3306-bib-0058){ref-type="ref"}, [59](#acn3306-bib-0059){ref-type="ref"} Thus, the mol oxysterol:mol CD ratio would be 0.00004, well below even the lowest solubilization capacity we measured. Therefore, while BBB penetration of CDs is limited,[17](#acn3306-bib-0017){ref-type="ref"} neuronal accessibility to these oxysterols which purportedly influence cellular cholesterol homeostasis and are the primary sterols that traverse the BBB[23](#acn3306-bib-0023){ref-type="ref"}, [24](#acn3306-bib-0024){ref-type="ref"} has the potential to be modulated through peripheral interactions with CDs.

In sum, complexation data showed incomplete correlation with efficacy for UC, an inverse correlation for GM2 and GM3, and the closest to a direct correlation for 24(*S*)‐HC. Substantial solubilization was also obtained for 27‐HC, sphingosine, and oleic acid. Potential influences on efficacy through CD interactions, particularly with sphingosine, gangliosides, and the oxysterols, merit further investigation, particularly in an environment that more closely mimics in vivo conditions. It may well be that the sum of CD interactions with several compounds, in turn altering their availability for endogenous molecular interactions, determines efficacy. Such influences could conceivably account for broader subcellular mechanisms that have been implicated in CD‐mediated disease amelioration. These mechanisms include induction of lysosomal exocytosis,[8](#acn3306-bib-0008){ref-type="ref"} TFEB‐meditated changes in lysosomal biogenesis,[9](#acn3306-bib-0009){ref-type="ref"} and modulation of the autophagic pathway.[60](#acn3306-bib-0060){ref-type="ref"} Rational development of improved CD‐based therapeutics can benefit from understanding the key interactions involved, but our empirical findings already demonstrate that efficacy and toxicity are not wholly inseparable, and viable alternatives to HP*β*CD are possible. Immediate goals should be long‐term efficacy studies of SBE‐CDs to fully understand their therapeutic value and validate lack of ototoxicity, with the hope of providing better options for NPC patients and their families.
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**Figure S1.** UC and GM2 and GM3 ganglioside accumulation in brain cells of 3‐week‐old mice treated with different commercial preparations of HP*β*CDs.
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Click here for additional data file.
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**Figure S2.** Ototoxicity of different CDs as assessed by ABR recordings.
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**Figure S3.** Correlation between reduction of gangliosides in *Npc1* ^*−/−*^ cerebral cortex and evidence of stable interaction with different CDs.

###### 

Click here for additional data file.

###### 

**Data S1.** Supplementary Materials and Methods.
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